Prospective Registry of EoSinophilic esOphagitis
Launched by IRCCS SAN RAFFAELE · Jun 4, 2024
Trial Information
Current as of February 12, 2025
Not yet recruiting
Keywords
ClinConnect Summary
Primary objective of the study is to create a registry of all EoE patients with \> 18 years of age referring to the Motility and EoE Unit of San Raffaele Hospital, in order to register clinical, endoscopic and histologic data on the disease, to further design and propose future prospective or retrospective studies to increase disease knowledge and foster collaborations with other centers nationally and internationally
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Participant is willing and able to give informed consent for participation in the study.
- • 2. The medical product is the standard of care for the patient or the participant is taking the medicinal product according to clinical practice
- • 3. Being diagnosed with EoE as per guidelines of the disease
- Exclusion Criteria:
- • 1. No clear diagnosis of EoE
- • 2. Not willing to provide informed consent to the inclusion in the registry
About Irccs San Raffaele
IRCCS San Raffaele is a prestigious research hospital and clinical trial sponsor based in Milan, Italy, renowned for its commitment to advancing medical science through innovative research and high-quality patient care. As an Institute for Research and Healthcare, it specializes in a wide range of therapeutic areas, including oncology, neurology, and cardiology, and is dedicated to translating scientific discoveries into effective clinical practices. With a multidisciplinary team of experts and state-of-the-art facilities, IRCCS San Raffaele plays a pivotal role in conducting rigorous clinical trials that contribute to the development of novel treatments and improve patient outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0